https://www.selleckchem.com/pr....oducts/napabucasin.h
Complement activation may play a pathogenic role in patients with severe coronavirus disease 2019 (COVID-19) by contributing to tissue inflammation and microvascular thrombosis. Serial samples were collected from patients receiving maintenance haemodialysis (HD). Thirty-nine patients had confirmed COVID-19 and 10 patients had no evidence of COVID-19. Plasma C5a and C3a levels were measured using enzyme-linked immunosorbent assay. We identified elevated levels of plasma C3a and C5a in HD patients with severe COVID-19 compared with co
Like
Comment
Share
